4D Molecular Therapeutics (FDMT) Accounts Payables (2019 - 2026)

4D Molecular Therapeutics (FDMT) has reported Accounts Payables for 8 consecutive years, with $14.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Accounts Payables rose 253.94% year-over-year to $14.7 million; the TTM figure through Mar 2026 stood at $14.7 million (up 253.94% YoY), while the FY2025 annual figure was $11.2 million, up 154.42% from the prior year.
• Accounts Payables climbed to $14.7 million in Q1 2026 per FDMT's latest filing, from $11.2 million in the prior quarter.
• Across five years, Accounts Payables topped out at $14.7 million in Q1 2026 and bottomed at $1.5 million in Q3 2022.
• Historically, Accounts Payables has averaged $5.0 million across 5 years, with a median of $3.5 million in 2023.
• Annual changes were most pronounced in 2022 — Accounts Payables tumbled 60.14% — and 2026, when it soared 253.94%.
• 4D Molecular Therapeutics' Accounts Payables stood at $3.3 million in 2022, then rose by 5.81% to $3.5 million in 2023, then advanced by 24.78% to $4.4 million in 2024, then surged by 154.42% to $11.2 million in 2025, then soared by 31.66% to $14.7 million in 2026.
• Business Quant data shows FDMT's Accounts Payables at $14.7 million in Q1 2026, $11.2 million in Q4 2025, and $6.9 million in Q3 2025.